Illumina to Repurchase Up to $120M of Stock | GenomeWeb
NEW YORK (GenomeWeb News) – Illumina said today that its board of directors has approved the repurchase of up to $120 million of its common stock.
 
"Given the underlying strength of Illumina's business and the recent turbulence in the equity markets, we think our current stock price is undervalued,” said Illumina President and CEO Jay Flatley. “Therefore, we believe the stock buy-back program is in the best interests of our stockholders.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.